NEWS & VIEWS

Global private equity and venture capital news and research

Posts Tagged ‘Versant Ventures’

26 June 2014

NVCF provides $10m to support Versant’s Canadian expansion

kanada Venture capital firm Northleaf Venture Catalyst Fund has provided $10m to Versant to fund the healthcare-focused venture capital firm’s expansion in Canada.

14 May 2014

Ceterix Orthopaedics venture backers re-up through $18m financing

Bone Therapeutics A trio of venture capital firms have renewed their commitment to surgical tool maker Ceterix Orthopaedics through an $18m financing round.

24 April 2014

Versant invests $25m in Series A for gene editing business CRISPR

dna Versant Ventures has led a $25m Series A financing round for biopharmaceutical business CRISPR Therapeutics, which is currently working on a breakthrough gene editing technology.

17 April 2014

H.I.G. BioVentures leads $15m VC round for ForSight VISION5

ForSight VISION5 has closed a $15m Series C round led by H.I.G. BioVentures, alongside returning investors Morgenthaler Ventures, Versant Ventures, Technology Partners, and Delphi Ventures.

15 April 2014

Gene therapy specialist AAVLife raises $12m in Versant-led Series A

heart_lrg Life sciences-focused venture capital firm Versant Ventures has led a $12m Series A round for gene therapy specialist AAVLife.

9 April 2014

Delphi Ventures leads new funding round for Sequent Medical

brain_lrg Delphi Ventures has recommitted to portfolio company Sequent Medical by leading a $20m Series D financing round.

28 March 2014

Venture firms renew commitment to RuiYi through $15m Series B round

dna Sino-American medical research business RuiYi has picked up another $15m of financing through a Series B round thanks to renewed commitments from its existing backers.

12 February 2014

VC backed Cadence Pharmaceuticals sells for $1.3bn

NYSE-listed pharmaceuticals company Mallinckrodt has agreed to acquire VC-backed Cadence Pharmaceuticals for $1.3bn.

10 January 2014

VC-backed pharma developer Flexion Therapeutics files for $86m IPO

Venture capital-backed pharmaceutical company Flexion Therapeutics could raise up to $86m for its IPO on the Nasdaq.

30 October 2013

Venture-backed cancer treatment business Immune Design scores up to $49m in Series C round

biomed_lrg Venture capital-backed biotech business Immune Design has collected up to $49m in Series C financing as it continues to develop immune-based therapies for cancer and other chronic conditions.

Page 1 of 212

Legals & Terms of UsePrivacy Policy


AltAssets is registered as a trademark of Investor Networks Limited (06695690).
Registered Office: Zetland House, 5-25 Scrutton St, London EC2A 4HJ
Content is © AltAssets 2000-2014